{"entity":{"id":"treeline-biosciences","kind":"company","name":"Treeline Biosciences","aka":[],"tldr":"Treeline Biosciences is a well-funded private company building cancer drugs of several kinds, including a pill that blocks all forms of the KRAS cancer protein and drugs for lymphoma.","summary":"Treeline Biosciences is a privately held, Watertown, Massachusetts biopharmaceutical company founded in 2021 that combines in-house inhibitor, protein degrader and antibody-drug conjugate capabilities with computational and machine-learning models. Its clinical programmes are TLN-121, a BCL6 degrader in phase 1 for B-cell and T-cell lymphomas; TLN-254, an EZH2 inhibitor (zeprumetostat, SHR2554) in-licensed from Jiangsu Hengrui for territories outside Greater China and in phase 1 in peripheral and cutaneous T-cell lymphoma; and TLN-372, a pan-KRAS inhibitor in phase 1 in solid tumours. Preclinical work extends to immunology and neurology. SEC Form D filings show more than 1 billion US dollars sold across private offerings between 2021 and 2025.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://treeline.bio/"},{"label":"Medicines (pipeline)","url":"https://treeline.bio/medicines"},{"label":"Form D (September 2025)","url":"https://www.sec.gov/Archives/edgar/data/1856619/000185661925000002/primary_doc.xml"}],"tags":[],"related":[],"cancers":["dlbcl"],"sections":["targeted-therapy","epigenetics"],"technologies":["protac-degrader","kras-inhibitors","epigenetic-drugs","ai-drug-design"],"targets":["kras","ezh2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The domain treelinebio.com does not resolve; the company site is treeline.bio. Round names and investors are not disclosed in the Form D filings or on the site. The dlbcl tag is an approximation for 'B-cell and T-cell lymphomas'."],"hq":"Watertown, MA","country":"US","companyType":"biotech","website":"https://treeline.bio/","founded":2021,"stage":"growth","investors":[],"funding":[{"round":"Form D offering","year":2021,"amountUsd":211669568,"source":"https://www.sec.gov/Archives/edgar/data/1856619/000185661921000001/primary_doc.xml","note":"Total sold per Form D filed April 2021"},{"round":"Form D offering","year":2022,"amountUsd":261266523,"source":"https://www.sec.gov/Archives/edgar/data/1856619/000185661922000003/primary_doc.xml","note":"Total sold per Form D filed October 2022"},{"round":"Form D offering","year":2024,"amountUsd":421779808,"source":"https://www.sec.gov/Archives/edgar/data/1856619/000185661924000002/primary_doc.xml","note":"Total sold per Form D filed October 2024"},{"round":"Form D offering","year":2025,"amountUsd":200099964,"source":"https://www.sec.gov/Archives/edgar/data/1856619/000185661925000002/primary_doc.xml","note":"Total sold of a 250 million US dollar offering per Form D filed September 2025"}]},"route":"/companies/treeline-biosciences/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"section":[{"id":"epigenetics","kind":"section","name":"Epigenetic & Transcriptional Therapy","route":"/fronts/epigenetics/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"ai-drug-design","kind":"technology","name":"AI-driven drug & target discovery","route":"/technologies/ai-drug-design/"},{"id":"epigenetic-drugs","kind":"technology","name":"Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)","route":"/technologies/epigenetic-drugs/"},{"id":"kras-inhibitors","kind":"technology","name":"KRAS & RAS inhibitors","route":"/technologies/kras-inhibitors/"},{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/"}],"target":[{"id":"ezh2","kind":"target","name":"EZH2","route":"/targets/ezh2/"},{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"}]}}